Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Early trial tests One-Shot cell therapy for eight serious autoimmune conditions

NCT ID NCT06548620

Summary

This early-phase study aimed to test the safety and initial effects of a new cell therapy called RD06-04 for people with serious autoimmune diseases like lupus, multiple sclerosis, and myasthenia gravis. The therapy involves modifying a patient's own immune cells (CAR-T cells) to target and reduce the harmful antibodies driving these diseases. The study was withdrawn before any participants were enrolled.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SLE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, 461499, China

Conditions

Explore the condition pages connected to this study.